nach oben

Targeted Oncology

Erschienen in:

01.09.2014 | Original Research

Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

verfasst von: Huijin Fan, Weixi Tian, Xiaofeng Ma

Erschienen in: Targeted Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Fatty acid synthase (FAS) is highly expressed in many kinds of human cancers, including liver cancer. Curcumin is the major active ingredient of Curcuma longa and has long been used to treat a variety of maladies. In the present study, we investigated the potential use of curcumin as a kind of FAS inhibitor for chemoprevention of liver cancer. Curcumin induced HepG2 cell apoptosis with the IC₅₀ value of 8.84 μg/ml. It inhibited intracellular FAS activity, and downregulated expression and mRNA level of FAS in a dose-dependent manner. In addition, sodium palmitate could rescue cell apoptosis induced by curcumin. Further studies reviewed that siRNA of FAS showed similar results as curcumin. These findings suggested that curcumin might be useful for preventing or treating liver cancer.

Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763–77PubMedCrossRef

Mashima T, Seimiya H, Tsuruo T (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Brit J Cancer 100:1369–72PubMedCentralPubMedCrossRef

Rossi S, Ou W, Tang D et al (2006) Gastrointestinal stromal tumours overexpress fatty acid synthase. J Pathol 209:369–75PubMedCrossRef

Flavin R, Peluso S, Lnguyen P (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6:551–62PubMedCentralPubMedCrossRef

Kuhajda FP, Pizer ES, Li JN et al (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. P Natl Acad Sci USA 97:3450–4CrossRef

Alò PL, Visca P, Trombetta G et al (1999) Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85:35–40PubMed

Gansler TS, Hardman W, Hunt DA et al (1997) Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol 28:686–92PubMedCrossRef

Innocenzi D, Alò PL, Balzani A et al (2003) Fatty acid synthase expression in melanoma. J Cutan Pathol 30:23–8PubMedCrossRef

Rashid A, Pizer ES, Moga M et al (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150:201–8PubMedCentralPubMed

10.

Sekiguchi M, Shiroko Y, Arai T et al (2001) Biological characteristics and chemosensitivity profile of four human anaplastic thyroid carcinoma cell lines. Biomed Pharmacother 55:466–74PubMedCrossRef

11.

Brusselmans K, De Schrijver E, Heyns W et al (2003) Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 106:856–862PubMedCrossRef

12.

Menendez JA, Lupu R (2004) Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp 52:414–26

13.

Puig T, Vázquez-Martín A, Relat J et al (2008) Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res Treat 109:471–9PubMedCrossRef

14.

Braga ME, Leal PF, Carvalho JE et al (2002) Comparison of yield, composition, and antioxidant activity of turmeric (Curcuma longa L.) extracts obtained using various techniques. J Agric Food Chem 51:6604–11CrossRef

15.

Khor TO, Keum YS, Lin W et al (2006) Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immune deficient mice. Cancer Res 66:613–21PubMedCrossRef

16.

Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225PubMedCrossRef

17.

Kunnumakkara AB, Guha S, Krishnan S et al (2007) Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB regulated gene products. Cancer Res 67:3853–61PubMedCrossRef

18.

Ravindran J, Prasad S, Aggarwal BB (2009) Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 11:495–510PubMedCentralPubMedCrossRef

19.

Wu SH, Hang LW, Yang JS et al (2010) Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade and mitochondria-dependent pathways. Anticancer Res 30:2125–33PubMed

20.

Xu Y, Zhang J, Han J et al (2012) Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of α1-antitrypsin in lung cancer. Mol Oncol 6:405–17PubMedCrossRef

21.

Ruby AJ, Kuttan G, Babu KD et al (1995) Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 94:79–83PubMedCrossRef

22.

Kumar V, Lewis SA, Mutalik S et al (2002) Biodegradable microspheres of curcumin for treatment of inflammation. Indian J Physiol Pharmacol 46:209–17PubMed

23.

Zhao J, Sun X, Ye F et al (2011) Suppression of fatty acid synthase, differentiation and lipid accumulation in adipocytes by curcumin. Mol Cell Biochem 351:19–28PubMedCrossRef

24.

Wang X, Tian W (2001) Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun 288:1200–6PubMedCrossRef

25.

Aggarwal BB, Shishodia S (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71:1397–421PubMedCrossRef

26.

Milgraum LZ, Witters LA, Pasternack GR et al (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in-situ breast carcinoma. Clin Cancer Res 3:2115–20PubMed

27.

Choi WI, Jeon BN, Park H et al (2008) Proto oncogene FBI-1 (Pokemon) and SREBP-1 synergistically activate transcription of fatty-acid synthase gene (FASN). J Biol Chem 283:29341–54PubMedCentralPubMedCrossRef

28.

Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66:5977–80PubMedCrossRef

29.

Bandyopadhyay S, Pai SK, Watabe M et al (2005) FAS expression inversely correlates with PTEN level in prostate cancer and a PI3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 24:5389–95PubMedCrossRef

30.

Radhakrishna PG, Srivastava AS, Hassanein TI et al (2004) Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 208:163–70CrossRef

31.

Atcher H, Planalp R, Cho J et al (2008) Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci 65:1631–52CrossRef

32.

Ströfer M, Jelkmann W, Depping R (2011) Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther Onkol 187:393–400PubMedCrossRef

33.

Aggarwal S, Ichikawa H, Takada Y et al (2006) Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaB alpha kinase and Akt activation. Mol Pharmacol 69:195–206PubMed

34.

Lin JK (2007) Molecular targets of curcumin. Adv Exp Med Biol 595:227–43PubMedCrossRef

35.

Pan MH, Lin-Shiau SY, Lin JK (2000) Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol 60:1665–76PubMedCrossRef

36.

Patel BB, Sengupta R, Qazi S et al (2008) Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122:267–73PubMedCrossRef

37.

Cheng AL, Hsu CH, Lin JK et al (2001) Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21:2895–900PubMed

38.

Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as “curecumin”: from kitchen to clinic. Biochem Pharmacol 75:787–809PubMedCrossRef

39.

Pizer ES, Wood FD, Heine HS et al (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189–93PubMed

Titel: Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase
verfasst von: Huijin Fan
Weixi Tian
Xiaofeng Ma
Publikationsdatum: 01.09.2014
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 3/2014
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-013-0286-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

New agents in renal cell carcinoma

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie